Special Issue "Antimicrobial Peptides for Therapeutic Applications"

A special issue of Biologics (ISSN 2673-8449).

Deadline for manuscript submissions: closed (1 May 2023) | Viewed by 3725

Special Issue Editor

Sub-Department of Pathophysiology, Department of Preclinical Veterinary Sciences, Faculty of Veterinary Medicine, University of Life Sciences, Akademicka 12, 20-033 Lublin, Poland
Interests: antimicrobial peptides and inflammatory cells, in particular the preparation of cathelicidins–peptides with antimicrobial activity, their isolation from natural sources (blood from some species of animals, cell cultures), their purification using biochemical techniques (gel chromatography, MS MALDI-TOF), and characterization of their properties, especially their influence on inflammatory cells and regulation of inflammation and tissue repair; alternative means such as antimicrobial peptides and proteins, which can can be offered as possible replacement for antibiotics which have lost their effectiveness due to microbial resistance; antimicrobial peptides involved in the regulation of inflammation and the regenerative process in some tissues

Special Issue Information

Dear Collegues,

It is my pleasure to announce a new Special Issue entitled “Antimicrobial Peptides for Therapeutic Applications”, for which I am serving as Guest Editor and to which I sincerely invite you to contribute your research work based on your expertise.

Antimicrobial peptides, also known as host defense peptides, are a promising group of naturally derived or synthetic products composed of short peptides with antimicrobial and immunomodulatory properties with potential for different clinical applications, e.g., regenerative medicine.

This Special Issue of Biologics will cover new research in the area of antimicrobial peptides as biologics. The focus of this issue will be on the interactions of antimicrobial peptides with host cells and the mechanism of their multiple biological functions, as well as the methods for their characterization. Additionally, research on clinical and pre-clinical experiments involved in the application of antimicrobial peptides in human medicine and on animal models is warmly welcome. We particularly welcome original research papers and reviews on the potential use or clinical application of antimicrobial peptides in biomedical sciences. Manuscripts are due on 31 December 2022, but earlier submissions are welcome, and they will be processed upon receipt and published online upon acceptance.

Dr. Joanna Wessely-Szponder
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biologics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • antimicrobial peptides
  • host defense peptides
  • cathelicidins
  • blood components
  • tissue repair
  • biologics
  • immunomodulators

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Therapeutic Role of Antimicrobial Peptides in Diabetes Mellitus
Biologics 2022, 2(1), 92-106; https://doi.org/10.3390/biologics2010008 - 18 Mar 2022
Cited by 3 | Viewed by 3209
Antimicrobial peptides (AMPs) have recently become widely publicized because they have the potential to function in alternative therapies as “natural” antibiotics, with their main advantage being a broad spectrum of activity. The potential for antimicrobial peptides to treat diabetes mellitus (DM) has been [...] Read more.
Antimicrobial peptides (AMPs) have recently become widely publicized because they have the potential to function in alternative therapies as “natural” antibiotics, with their main advantage being a broad spectrum of activity. The potential for antimicrobial peptides to treat diabetes mellitus (DM) has been reported. In diabetes mellitus type I (T1D), cathelicidin-related antimicrobial peptide (CRAMP), cathelicidin antimicrobial peptide (CAMP) and mouse-β- defensin 14 (mBD14) are positively affected. Decreased levels of LL-37 and human neutrophil peptide 1-3 (HNP1-3) have been reported in diabetes mellitus type II (T2D) relative to healthy patients. Moreover, AMPs from amphibians and social wasps have antidiabetic effects. In infections occurring in patients with tuberculosis-diabetes or diabetic foot, granulysin, HNP1, HNP2, HNP3, human beta-defensin 2 (HBD2), and cathelicidins are responsible for pathogen clearance. An interesting alternative is also the use of modified M13 bacteriophages containing encapsulated AMPs genes or phagemids. Full article
(This article belongs to the Special Issue Antimicrobial Peptides for Therapeutic Applications)
Back to TopTop